+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (2.5 g Type, Other Concentrations / Presentations), By Application (Complicated Intra-abdominal Infection, Hospital-acquired Pneumonia, Ventilator-associated Pneumonia, Complicated UTI / Other Resistant Infections), By End User (Hospitals, Specialty Clinics, Critical Care Centers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online / Specialty Channels), By Treatment Type (Targeted Monotherapy, Combination Therapy, Step-down / Sequential Therapy), and Regional Forecast, 2026-2034
The global Ceftazidime Avibactam market was valued at USD 1.20 billion in 2025 and is estimated at USD 1.32 billion in 2026. The market is projected to reach USD 2.80 billion by 2034, exhibiting a 9.9% CAGR during 2026–2034.
Ceftazidime-avibactam is a fixed-dose intravenous antibacterial combining ceftazidime, a third-generation cephalosporin, with avibactam, a non-beta-lactam beta-lactamase inhibitor. In the United States, AVYCAZ is indicated for complicated intra-abdominal infection in combination with metronidazole, complicated urinary tract infection including pyelonephritis, and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia caused by designated susceptible Gram-negative organisms.
The commercial importance of the combination is closely linked to antimicrobial resistance. WHO reported in October 2025 that one in six laboratory-confirmed bacterial infections causing common infections worldwide in 2023 were resistant to antibiotics. More than 55% of Klebsiella pneumoniae globally were resistant to third-generation cephalosporins, while resistance to carbapenems is also increasing in multiple regions. Ceftazidime-avibactam is therefore used primarily in hospitals and critical-care settings where resistant Gram-negative pathogens substantially narrow treatment options.
Current IDSA 2026 guidance places ceftazidime-avibactam among preferred agents for invasive infections caused by KPC-producing Enterobacterales and identifies it as the preferred option for OXA-48-like-producing Enterobacterales. At the same time, the resistance mechanism matters: avibactam does not inhibit metallo-beta-lactamases such as NDM, and the 2026 ECDC CRE25 preliminary analysis found a rising share of NDM-producing Klebsiella pneumoniae in Europe. This creates both a strong KPC/OXA-48 treatment niche and an important resistance-related limit to future use.
The study covers ceftazidime-avibactam combination products used for serious Gram-negative infections, preserving the core type, application, end-user, distribution-channel and treatment-approach segmentation while aligning clinical context with current labeling and resistance guidance.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | 2.5 g Type; Other Concentrations / Presentations |
| By Application | Complicated Intra-abdominal Infection; Hospital-acquired Pneumonia; Ventilator-associated Pneumonia; Complicated UTI / Other Resistant Infections |
| By End User | Hospitals; Specialty Clinics; Critical Care Centers |
| By Distribution Channel | Hospital Pharmacies; Retail Pharmacies; Online / Specialty Channels |
| By Treatment Type | Targeted Monotherapy; Combination Therapy; Step-down / Sequential Therapy |
| By Resistance Mechanism | KPC-producing Enterobacterales; OXA-48-like Enterobacterales; Selected Resistant Pseudomonas; MBL-associated Infections with Partner Therapy |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Allergan / AbbVie; Pfizer Inc.; QILU Pharmaceutical; GlaxoSmithKline plc; Merck & Co.; Novartis AG; Zydus Lifesciences; Aurobindo Pharma; Lupin Limited; Dr. Reddy's Laboratories; Cipla Ltd.; Sun Pharmaceutical Industries; Hetero Drugs; Fresenius Kabi; Viatris |
WHO's 2025 global surveillance shows widespread resistance in E. coli and K. pneumoniae and worsening resistance to multiple antibiotic classes. Hospitals increasingly need newer beta-lactam/beta-lactamase inhibitor combinations when routine cephalosporins or carbapenems are inactive.
IDSA 2026 guidance emphasizes identifying the specific carbapenemase mechanism. Ceftazidime-avibactam is highly active against many KPC and OXA-48-like producers but does not directly inhibit NDM, VIM or IMP metallo-beta-lactamases.
AVYCAZ labeling states that the drug should be used only for infections proven or strongly suspected to be caused by susceptible organisms. Antimicrobial stewardship therefore concentrates use in severe infections with microbiological or strong epidemiologic justification.
Ceftazidime and avibactam are renally cleared and dosing must be reduced in impaired renal function. Rapidly changing renal function in critically ill patients can complicate exposure and requires close monitoring.
IDSA reports resistance emergence during ceftazidime-avibactam treatment in approximately 10% of reported KPC-E cases, often through KPC variants. Preserving activity therefore requires susceptibility testing, optimized dosing and avoidance of unnecessary exposure.
The updated guidance identifies ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam as preferred KPC-E treatments and ceftazidime-avibactam as preferred for OXA-48-like Enterobacterales. This supports continued high-value use in microbiologically defined hospital infections.
Molecular tests capable of detecting KPC, OXA-48, NDM, VIM and IMP can guide early selection among newer beta-lactams. Faster mechanism identification can reduce ineffective empiric therapy and improve stewardship of reserve antibiotics.
China, India and other Asia-Pacific markets combine high resistant Gram-negative burden with expanding tertiary hospitals. The market outlook includes faster growth in China as local manufacturing and hospital access improve.
FDA approved aztreonam-avibactam in 2025 for selected complicated intra-abdominal infections with limited treatment options. It addresses metallo-beta-lactamase producers differently from ceftazidime-avibactam and reshapes how avibactam-based therapy is positioned.
WHO GLASS and ECDC genomic surveillance provide more detailed regional resistance patterns. Countries with higher KPC or OXA-48-like prevalence may have greater ceftazidime-avibactam use than markets where NDM dominates.
Clinical value is defined less by infection site alone than by pathogen susceptibility and beta-lactamase mechanism. The same infection syndrome can require different agents depending on carbapenemase genotype.
| Resistance / Infection Context | Current Role | Commercial Relevance |
|---|---|---|
| KPC-producing Enterobacterales | IDSA lists ceftazidime-avibactam among preferred agents; U.S. surveillance data show greater than 95% activity. | Core high-value CRE indication. |
| OXA-48-like Enterobacterales | IDSA identifies ceftazidime-avibactam as the preferred treatment option. | Major relevance in Europe, Middle East and other OXA-48-endemic settings. |
| NDM / other MBL Enterobacterales | Ceftazidime-avibactam alone is not active against MBLs; aztreonam-avibactam is preferred, or ceftazidime-avibactam plus aztreonam can be used when appropriate. | Limits standalone use where NDM prevalence is high. |
| Complicated UTI / pyelonephritis | FDA-approved indication against designated susceptible Gram-negative organisms. | Important hospital and severe-UTI application. |
| cIAI | FDA-approved with metronidazole. | Large surgical and critical-care application. |
| HABP / VABP | FDA-approved in adults for designated susceptible Gram-negative pathogens. | High-value ICU application with long treatment courses. |
The 2.5 g Type dominates with more than 60% share because it corresponds to the standard adult AVYCAZ dose in patients with creatinine clearance above 50 mL/min.
Each standard adult dose contains ceftazidime 2 g plus avibactam 0.5 g and is administered every eight hours over a two-hour infusion in patients with normal renal function. This presentation therefore drives the largest share of hospital utilization.
Other presentation needs are driven by regional packaging, pediatric dosing and renal adjustment. Hospitals may prepare reduced doses from standard vials according to prescribing information and pharmacy protocols.
Complicated Intra-abdominal Infection is a major source-segment application, while pneumonia and cUTI contribute substantial inpatient use. All indications depend on susceptible Gram-negative pathogens and stewardship oversight.
AVYCAZ is used with metronidazole for cIAI caused by designated susceptible Gram-negative organisms. Surgical source control and polymicrobial coverage remain essential to overall treatment success.
HABP is associated with resistant Enterobacterales and Pseudomonas in hospitalized patients. Ceftazidime-avibactam offers a targeted option when susceptibility and resistance mechanism support use.
VABP occurs in mechanically ventilated patients with high illness severity and resistant pathogen risk. IV reserve antibiotics command high treatment value in this setting.
cUTI including pyelonephritis is an FDA-approved indication. Off-label or mechanism-directed use in other serious infections is guided by susceptibility, professional guidance and specialist judgment.
Hospitals constitute the largest end-user group because treatment is intravenous and concentrated in seriously ill patients with multidrug-resistant Gram-negative infection.
Tertiary hospitals combine infectious-disease specialists, microbiology laboratories, antimicrobial-stewardship programs, ICU care and renal monitoring required for appropriate use.
Outpatient infectious-disease and infusion services may support continuation therapy in selected stable patients, but the channel remains much smaller than inpatient use.
ICUs generate disproportionate use because HABP/VABP, sepsis and severe CRE infections are concentrated in critically ill patients with prior antibiotic exposure.
Hospital Pharmacies dominate distribution because the product is an intravenous reserve antibiotic used under institutional stewardship and requires pharmacy preparation and renal-adjusted dosing.
Hospital formularies control access, reconstitution, dosing, renal adjustment and antibiotic-use authorization. Group purchasing and formulary negotiation strongly influence pricing.
Retail dispensing is limited because ceftazidime-avibactam is an IV product. Use can occur when specialty infusion arrangements support outpatient parenteral antimicrobial therapy.
Specialty distributors and home-infusion supply chains can support selected continuation therapy, but this remains a small share compared with institutional hospital purchasing.
Targeted Monotherapy with a microbiologically active beta-lactam is the evidence-based core for many susceptible CRE infections. Combination therapy retains defined roles when the resistance mechanism requires a partner drug or while empiric coverage is being clarified.
IDSA 2026 guidance does not routinely suggest continued combination therapy once an active beta-lactam has been identified for CRE. Ceftazidime-avibactam monotherapy is therefore central when the isolate is susceptible and mechanism-appropriate.
Combination is relevant in selected situations, most notably ceftazidime-avibactam plus aztreonam when an NDM-producing Enterobacterales infection requires an avibactam-protected aztreonam strategy and aztreonam-avibactam is unavailable.
Because ceftazidime-avibactam is intravenous, step-down typically means transition to another susceptible oral or parenteral agent once the patient stabilizes and cultures permit narrower therapy.
North America is the largest regional market. The United States alone was valued at approximately USD 450 million in 2025, representing about 37.5% of global market value. Large academic hospitals, rapid diagnostics, infectious-disease specialists and reimbursement for high-cost reserve antibiotics support use.
Europe has substantial demand because of rising CRE prevalence and strong tertiary-care stewardship. ECDC reported worsening carbapenem-resistant Klebsiella pneumoniae spread in multiple countries and 2026 surveillance shows changing carbapenemase patterns, with OXA-48-like and NDM distributions directly affecting drug choice.
Asia-Pacific is the fastest-growing major region. China is expected to reach approximately USD 380 million by 2034. High AMR burden, expanding tertiary hospitals and local pharmaceutical manufacturing create strong demand, but affordability and NDM prevalence influence the addressable market.
Brazil, Mexico and major referral hospitals in other countries drive use. Carbapenemase-producing Gram-negative infections are an important clinical problem, but premium antibiotic cost and uneven rapid-testing access limit broader adoption.
The Middle East has meaningful OXA-48-like Enterobacterales prevalence and advanced GCC hospitals use newer beta-lactam combinations. In Africa, clinical need is high but access is constrained by diagnostic capacity, drug cost and hospital infrastructure.
Ceftazidime-avibactam is a reserve antibacterial whose commercial use is tightly linked to susceptibility testing, renal dosing and stewardship policy.
| Requirement / Evidence | Current Position | Market Effect |
|---|---|---|
| FDA AVYCAZ labeling | Approved for cIAI with metronidazole, cUTI including pyelonephritis, and HABP/VABP against designated susceptible Gram-negative organisms. | Defines the U.S. labeled treatment base. |
| Adult dosing | 2.5 g every 8 hours by 2-hour infusion when creatinine clearance is greater than 50 mL/min. | Makes the 2.5 g vial/presentation the dominant commercial type. |
| IDSA 2026 CRE guidance | Preferred for OXA-48-like Enterobacterales and one of the preferred options for KPC-E. | Strengthens mechanism-directed specialist use. |
| WHO 2025 AMR surveillance | One in six lab-confirmed bacterial infections in 2023 were resistant; Gram-negative resistance is a major global threat. | Sustains long-term clinical need. |
| ECDC CRE25 findings | Rising NDM prevalence in European K. pneumoniae may reduce suitability of ceftazidime-avibactam monotherapy in some settings. | Creates resistance-mechanism risk and demand for alternatives. |
The branded market is concentrated around the AVYCAZ/ZAVICEFTA franchise, while regional manufacturers and future generic entrants broaden competition. Newer beta-lactam/beta-lactamase inhibitor products also compete by resistance mechanism.
AVYCAZ is the U.S. brand for ceftazidime-avibactam. AbbVie maintains product support and institutional access infrastructure in North America.
Pfizer commercializes ceftazidime-avibactam as ZAVICEFTA in many markets outside North America and provides current international labeling and antimicrobial information.
Chinese and Indian pharmaceutical manufacturers are expanding beta-lactam/beta-lactamase inhibitor portfolios, creating increasing price and access competition across Asia.
Large injectable and anti-infective manufacturers have the scale, sterile manufacturing and hospital distribution required to compete as regional approvals and intellectual-property conditions permit.
Clinical competition is increasingly determined by KPC, OXA-48, NDM and other resistance mechanisms rather than by one broad CRE category.
August 2026: IDSA published updated guidance for antimicrobial-resistant Gram-negative infections, retaining ceftazidime-avibactam among preferred therapies for KPC-producing Enterobacterales and identifying it as the preferred treatment for OXA-48-like-producing Enterobacterales.
16 July 2026: WHO updated its antimicrobial-resistance fact sheet, reporting that approximately one in six laboratory-confirmed bacterial infections worldwide in 2023 were resistant to antibiotics and highlighting drug-resistant Gram-negative pathogens as a major global threat.
29 June 2026: ECDC published preliminary CRE25 findings showing a rising proportion of NDM carbapenemase genes in carbapenem-resistant Klebsiella pneumoniae across the EU/EEA, a clinically important shift because ceftazidime-avibactam is not active against NDM producers by itself.
13 May 2026: ECDC published results from its large multi-country genomic survey of carbapenem- and/or colistin-resistant Enterobacterales, covering isolates from 323 hospitals in 36 European countries and reinforcing the need for mechanism-specific therapy.
7 February 2025: FDA approved EMBLAVEO (aztreonam-avibactam) for selected complicated intra-abdominal infections with limited treatment options, adding a new avibactam-based competitor particularly relevant to metallo-beta-lactamase-producing Enterobacterales.
The global Ceftazidime Avibactam market is projected to grow from USD 1.32 billion in 2026 to USD 2.80 billion by 2034, at a 9.9% CAGR. Growth will be driven by resistant Gram-negative infections, rapid diagnostics and expanding hospital access, while NDM prevalence, stewardship and newer beta-lactamase inhibitor combinations shape the achievable market.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| AMR burden | WHO surveillance shows widespread and increasing resistance. | Expands need for reserve antibiotics. |
| KPC / OXA-48 detection | Molecular carbapenemase testing is becoming more available. | Supports targeted use of ceftazidime-avibactam. |
| NDM expansion | ECDC 2026 data show rising NDM in European K. pneumoniae. | Limits standalone activity in some markets. |
| Hospital stewardship | Reserve-antibiotic use is increasingly protocolized. | Improves appropriate use but limits indiscriminate volume. |
| Asia-Pacific access | Tertiary hospitals and local manufacturing continue to expand. | Creates strongest regional growth. |
The study supports hospital anti-infective strategy, antimicrobial-stewardship planning, product positioning, regional market access and competitive benchmarking.
Market sizing combines bottom-up product, supplier, pricing and utilization analysis with top-down demand validation. Quantitative inputs include treated-patient volumes, product launches, generic or biosimilar penetration, distribution mix, regional access, pricing and relevant disease burden.
Primary research validates prescribing or procurement patterns, treatment workflows, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health agencies, professional guidance, peer-reviewed evidence and official company sources. Forecast assumptions are cross-checked against regulatory activity, patent and exclusivity cycles, market access, resistance or disease trends and regional healthcare capacity.
Forecasts incorporate resistant Gram-negative infection burden, hospital utilization, KPC and OXA-48-like prevalence, NDM-related limitations, 2.5 g presentation share, U.S. and China market trajectories, average treatment value, stewardship restrictions and regional access. North America remains the largest value market, while Asia-Pacific receives the strongest growth assumptions.
The market was valued at USD 1.20 billion in 2025 and is estimated at USD 1.32 billion in 2026. It is projected to reach USD 2.80 billion by 2034, representing a 9.9% CAGR.
The 2.5 g Type is the leading formulation with more than 60% share and corresponds to the standard adult AVYCAZ dose of 2 g ceftazidime plus 0.5 g avibactam in patients with normal renal function.
North America is the largest regional market. The United States represented approximately USD 450 million in 2025.
Current U.S. indications include complicated intra-abdominal infection with metronidazole, complicated urinary tract infection including pyelonephritis, and hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible Gram-negative organisms.
Ceftazidime-avibactam is particularly important for KPC- and OXA-48-like-producing Enterobacterales. It is not active alone against NDM and other metallo-beta-lactamases.
No. The 2026 IDSA guidance does not routinely suggest continued combination therapy once an active beta-lactam has been identified, although mechanism-specific combinations can be appropriate in selected infections.
The report profiles Allergan/AbbVie, Pfizer, QILU Pharmaceutical, GSK, Merck, Novartis, Zydus, Aurobindo, Lupin, Dr. Reddy's, Cipla, Sun Pharma, Hetero, Fresenius Kabi and Viatris.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
